Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Allantoicase is an enzyme (systematic name: allantoate amidinohydrolase, EC 3.5.3.4) that catalyzes the hydrolysis of allantoate to (S)-ureidoglycolate and urea, as part of the purine degradation pathway. It belongs to the hydrolase family, specifically acting on carbon-nitrogen bonds in linear amidines. The enzyme is hexameric (dimer of trimers), with each subunit showing a jelly-roll beta-sheet motif, and the active site is formed by conserved surface patches at the interface of these motifs[1][2][4][5][7]. While important for nitrogen recycling in plants, microorganisms, fish, and amphibians, the human genome encodes a homolog (ALLC) that appears to be functionally inactive; thus, there is no established role for human disease or as a therapeutic target[1][6]. No drugs or biomarkers are currently associated with allantoicase, and there are no known safety concerns.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Allantoicase (ALLC).